[The significance of betamimetics and magnesium for the outcome of pregnancy: II. The role of magnesium in the development of gestosis and fetal hypotrophy].
Of 4905 single pregnancies between 1979 and 1982 the 882 (18.0%) risk pregnancies managed tocolytically with Betamimetics and Magnesium were retrospectively compared with the remaining collective (R) of 4023 (82.0%) patients without management. The tocolysed patients (B/Mg) received Magnesium in addition to Betamimetics: since 1979/1980 a low dose Mg containing drug (Feto-Longoral) aimed at "cardioprotection" (3-6 mval Mg++ daily), and since 1981 to "support tocolysis" 30-40 mval Mg++ daily per os in the form of Mg-aspartate (Mg 5-Longoral). All cases of gestosis (G) in both collectives B/Mg and R were investigated. A normal collective (N) is obtained by subtracting G from R. For all collectives N, G, and B/Mg the following data were compared: mean age, parity, percentage with supplement Mg medication (only the B/Mg collective), the pregnancy outcome with respect to pregnancy duration and the number of intrauterine retarded infants (IUR: less than 10th percentile of the Bavarian Perinatal Evaluation (BPE), less than 25th percentile according to Hohenauer). The number of gestosis in the 882 B/Mg cases is zero. It is 97 (2.0%) in the remaining 4023 patients. The IUR rate (less than 10th perc. BPE) is 9.4% in the 3926 N patients, and is 45.4% in the 97 gestosis patients. The IUR rate is 17.8% in the 398 B/Mg patients of 1979 and 1980 who had received less adjuvant Mg (B/Mg [1]), and it is 10.1% in the 484 B/Mg patients of 1981 and 1982 who had received much higher Magnesium (B/Mg [2]).(ABSTRACT TRUNCATED AT 250 WORDS)